https://doctransparency.com/doctor/tx/plano/annette-okai-1275755399
Medicare Enrolled

Dr. Annette Okai, MD

Neurology · Plano, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Speaking/Promotional
5425 W SPRING CREEK PKWY STE 275, Plano, TX 75024
9724038184
In practice since 2007 (18 years)
NPI: 1275755399 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Okai from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Okai? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Okai

Dr. Annette Okai is a neurology in Plano, TX, with 18 years in practice. Based on federal Medicare data, Dr. Okai performed 587 Medicare services across 141 unique beneficiaries.

Between the years covered by Open Payments, Dr. Okai received a total of $932,365 from 64 pharmaceutical and/or device companies across 1692 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Okai is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice▲ Top 44% volume in TX$ $932,365 industry payments

Medicare Practice Summary

Medicare Utilization ↗
587
Medicare services
Top 44% in TX for neurology
141
Unique beneficiaries
$26
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~33 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
MRI contrast dye injection (gadoterate)420$0$10
Office visit, established patient (30-39 min)90$81$175
Blood draw (venipuncture)45$7$25
Mri scan of brain before and after contrast18$223$1,000
Mri scan of upper spinal canal before and after contrast14$242$1,400
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$932,365
Total received (2018-2024)
Avg $133,195/year across 7 years
Top 0% in TX for neurology
64
Companies
1,692
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$587,179 (63.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$332,433 (35.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,753 (1.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$43,300
2023
$94,730
2022
$125,790
2021
$81,639
2020
$87,517
2019
$236,283
2018
$263,107

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
GENZYME CORPORATION
$339,049
Biogen, Inc.
$143,138
Genentech USA, Inc.
$117,557
EMD Serono, Inc.
$95,569
Celgene Corporation
$64,252
Merck KGaA
$38,403
Alexion Pharmaceuticals, Inc.
$35,471
Teva Pharmaceuticals USA, Inc.
$26,712
Genentech, Inc.
$19,385
Novartis Pharmaceuticals Corporation
$13,175
E.R. Squibb & Sons, L.L.C.
$12,903
SANOFI-AVENTIS U.S. LLC
$5,779
TG THERAPEUTICS, INC.
$5,387
Horizon Therapeutics plc
$4,817
Greenwich Biosciences, Inc.
$3,677
Amgen Inc.
$1,376
Merz Pharmaceuticals, LLC
$667
ABBVIE INC.
$639
Ipsen Biopharmaceuticals, Inc
$490
Lundbeck LLC
$384
Lilly USA, LLC
$338
Axsome Therapeutics, Inc.
$319
Avanir Pharmaceuticals, Inc.
$291
TG Therapeutics, Inc.
$272
UCB, Inc.
$219
Biohaven Pharmaceutical Holding Company Ltd.
$195
Biohaven Pharmaceuticals, Inc.
$193
Acorda Therapeutics, Inc
$173
Grifols USA, LLC
$147
Mallinckrodt Enterprises LLC
$128
SCILEX PHARMACEUTICALS INC.
$126
UPSHER-SMITH LABORATORIES LLC
$83
Otsuka America Pharmaceutical, Inc.
$81
JAZZ PHARMACEUTICALS INC.
$71
Inspire Medical Systems, Inc.
$67
Harmony Biosciences LLC
$64
Bayer HealthCare Pharmaceuticals Inc.
$62
IMPEL PHARMACEUTICALS INC.
$60
AbbVie Inc.
$45
ACADIA Pharmaceuticals Inc
$45
BANNER LIFE SCIENCES, LLC
$41
Allergan, Inc.
$41
SK Life Science, Inc.
$38
Janssen Pharmaceuticals, Inc
$37
Scilex Pharmaceuticals Inc.
$37
ARGENX US, INC.
$31
Shire North American Group Inc
$31
Sumitomo Pharma America, Inc.
$28
Akcea Therapeutics, Inc.
$27
Arbor Pharmaceuticals, Inc.
$24
Supernus Pharmaceuticals, Inc.
$21
Abbott Laboratories
$19
GRT US Holding, Inc.
$19
Amneal Pharmaceuticals LLC
$18
HARMONY BIOSCIENCES LLC
$18
Upsher-Smith Laboratories LLC
$17
Allergan Inc.
$17
Tonix Medicines, Inc.
$16
Mylan Pharmaceuticals Inc.
$15
Azurity Pharmaceuticals, Inc.
$14
Currax Pharmaceuticals LLC
$14
PFIZER INC.
$14
Kyowa Kirin, Inc.
$13
OWP Pharmaceuticals, Inc.
$12
Top 3 companies account for 64.3% of total payments
Associated products mentioned in payments ›
ACTHAR · ADUHELM · AIMOVIG · AJOVY · ALTUVIIIO · AMPYRA · AMYVID · APTIOM · AUBAGIO · AVONEX · Aimovig · Austedo XR · BAFIERTAM · BOTOX · BRIUMVI · Betaseron · Briviact · COPAXONE · DISEASE STATE · DYSPORT · Dysport · EMGALITY · Edarbi · Enspryng · Epidiolex · Fintepla · GILENYA · Gamunex-C · Glatiramer Acetate · HORIZANT · Horizant · INBRIJA · INFINITY · INSPIRE · KESIMPTA · LEMTRADA · LYVISPAH · Lamotrigine Starter Kit · MAVENCLAD · MAYZENT · MS DISEASE STATE · Mavenclad · NO PRODUCT DISCUSSED · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Nuedexta · OCREVUS · ONZETRA XSAIL · Ocrevus · Ozanimod · PIPELINE-MS · PLEGRIDY · Ponvory · QULIPTA · Qutenza · RAYOS · RINVOQ · Rebif · Rystiggo · SKYRIZI · SOLIRIS · Soliris · Sunosi · TECFIDERA · TEGSEDI · TOSYMRA · TOSYMRA SUMATRIPTAN NASAL SPRAY · TROKENDI XR · TYSABRI · Trudhesa · Tysabri · UBRELVY · ULTOMIRIS · UPLIZNA · VPRIV · VUMERITY · VYEPTI · VYVGART HYTRULO · WAKIX · Wakix · XYWAV · Xeomin · ZEMBRACE SYMTOUCH · ZEPOSIA · ZTLido
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (63%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for neurology in TX.

Equivalent to $158,836 per 100 Medicare services performed
Looking for a neurology in Plano?
Compare neurologys in the Plano area by procedure volume, costs, and industry payment transparency.
Browse neurologys nearby

Geographic Context

Neurologys within 10 mi
231
Per 100K population
20.7
County median income
$117,588
Nearest hospital
CHILDRENS MEDICAL CENTER PLANO
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Okai is a clinical cardiology specialist, with moderate Medicare volume, and high industry engagement (speaking/promotional, top 0%), with 18 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Okai experienced with mri contrast dye injection (gadoterate)?
Based on Medicare claims data, Dr. Okai performed 420 mri contrast dye injection (gadoterate) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Okai receive payments from pharmaceutical companies?
Yes. Dr. Okai received a total of $932,365 from 64 companies across 1,692 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Okai's costs compare to other neurologys in Plano?
Dr. Okai's average Medicare payment per service is $26. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Okai) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →